Nexstar Media Group Inc (NXST) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges ...
Distribution Revenue: $762 million, increased by 0.1% over the prior year quarter.
Advertising Revenue: $460 million, decreased by 10.2% over the prior year quarter.
Political Advertising Revenue: $6 million, a decrease of $32 million from the prior year.
Adjusted EBITDA: $381 million, representing a 30.9% margin, decreased by $71 million from the prior year.
Adjusted Free Cash Flow: $348 million, compared to $389 million last year.
Capital Expenditures (CapEx): $35 million, a decrease from $44 million in the prior year.
Net Interest Expense: $97 million, a reduction of $17 million from the prior year.
Outstanding Debt: $6.5 billion, a reduction of $28 million for the quarter.
Cash Balance: $253 million at quarter end.
First Lien Covenant Ratio: 1.67 times, well below the covenant of 4.25 times.
Total Net Leverage: 2.93 times at quarter end.
Warning! GuruFocus has detected 4 Warning Signs with NXST.
Release Date: May 08, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Nexstar Media Group Inc (NASDAQ:NXST) reported a strong start to 2025 with solid financial results, including record first quarter distribution revenue.
The company is well-positioned to capitalize on potential deregulation, which could lead to strategic mergers and acquisitions.
Nexstar's diversified revenue streams, with 63% coming from distribution and other sources, provide stability amid economic uncertainties.
The CW network showed significant improvement, with its strongest primetime performance in eight quarters, driven by new content strategies.
News Nation continues to grow its audience, outperforming competitors like MSNBC and CNN in key demographics, and gaining recognition as a trusted national news source.
Nexstar Media Group Inc (NASDAQ:NXST) experienced a 3.9% decline in net revenues compared to the prior year, primarily due to a reduction in political advertising.
The advertising market remains challenging, with a 10.2% decrease in advertising revenue, impacted by softness in the television advertising market.
Subscriber attrition continues to be a concern, although there are signs of marginal improvement in subscriber trends.
The CW network's profitability declined in the first quarter due to increased sports programming amortization.
The company faces potential risks from elevated interest rates and reduced maximum leverage, affecting the cost of capital for new transactions.
Q: What is the expected timeline for regulatory changes if the fifth FCC commissioner is confirmed soon? A: Perry Sook, Chairman and CEO, indicated that an NPRM (Notice of Proposed Rulemaking) could be one of the first actions taken by the FCC Chairman to revisit ownership rules. He expects momentum in Washington to continue, with potential M&A activity coming into focus as the year progresses.
Q: Are you comfortable with beginning transactions under the conditionality of the FCC's new procedures if an NPRM is issued? A: Perry Sook stated that Nexstar is willing to take calculated risks for opportunities, and they would consider putting pen to paper during the pendency of an NPRM, depending on circumstances and having a willing counterparty.
Q: How is the current advertising market performing, and what are the expectations for the rest of the year? A: Lee Gliha, CFO, noted that the advertising market is currently down in the mid-single digits year-over-year, similar to Q1 results. They expect a pickup in the back half of the year due to the elimination of crowd-out effects.
Q: How do you prioritize between expanding your national footprint and increasing in-market duopolies? A: Perry Sook emphasized that growing the national footprint has more strategic importance than adding a second or third station in a market. However, both have strategic importance, and they focus on acquisitions that are more accretive than buying back stock.
Q: What is the impact of the current regulatory environment on potential M&A activities? A: Perry Sook mentioned that the DOJ understands the need for marketplace realities in transactions, and there is broad agreement in the industry for consolidation. The NAB board unanimously supports eliminating national cap and in-market ownership restrictions, which could facilitate M&A activities.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Verge
6 minutes ago
- The Verge
Democrats ask how Trump's government will regulate Trump Mobile
When a Trump-branded phone on a Trump-branded mobile network launches sometime this year (if all goes according to plan), US regulators will face what's become a recurring conundrum in Donald Trump's presidency: how to regulate a product with ties to the head of state. Six Democratic lawmakers are confronting key federal agencies with that very question in a letter shared exclusively with The Verge. Led by Sen. Elizabeth Warren (D-MA), the lawmakers ask the Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food and Drug Administration (FDA), the departments of Commerce and Treasury, and US Trade Representative's (USTR) Office about how they'll avoid 'undue political influence' and what they'd do if they were asked by the White House to stop investigating potentially unlawful practices by Trump Mobile. The lawmakers, including Sens. Richard Blumenthal (D-CT), Adam Schiff (D-CA), Chris Van Hollen (D-MD), as well as Reps. Doris Matsui (D-CA) and Greg Casar (D-TX), singled out the six entities because of the role they could play in regulating Trump Mobile's operations. The FCC is tasked with regulating mobile virtual network operators (MVNOs) like Trump Mobile across state lines. The FTC enforces laws against consumer deception, including claims of products being made in the US, as the Trump Mobile phone was initially said to be. The FDA regulates medical devices including some software apps, which could include the telehealth service that Trump Mobile claims can help read vital signs with a phone camera. The departments of Commerce and Treasury and the USTR oversee tariff policy, which the lawmakers fear could be exploited to benefit Trump Mobile. They note that Trump exempted smartphones from his tariffs after meeting with and receiving a million-dollar donation from Apple CEO Tim Cook, and 'the opportunities for corruption and self-dealing will be even greater as Trump Mobile ramps up its business.' The lawmakers acknowledge that Trump Mobile says its offerings are not 'designed, developed, manufactured, distributed or sold by The Trump Organization or any of their respective affiliates or principals.' But selling a trademark license for the Trump name can still be lucrative for the president, since the company that controls it is owned by his trust. The president earned $8 million by licensing his name to products last year, NPR reported. It's not the first time that Trump family businesses have raised potential conflict of interest concerns — critics warned that the president's support for bills boosted by the cryptocurrency industry could ultimately help his own family's stablecoin ventures, even though the White House says Trump's own assets are in a trust managed by his kids. The Democrats are also worried that other companies — like mobile network carriers or phone retailers — will offer Trump Mobile favorable terms to help their own dealings with the government. Tech CEOs have wasted no time trying to get on the administration's good side, including by donating millions to Trump's inaugural fund. 'Trump Mobile offers yet another avenue for tech and telecom companies to purchase influence with President Trump, such as by offering Trump Mobile favorable conditions for MVNO arrangements like preferential network access or pricing arrangements, making their proprietary apps available on the Trump Mobile platform, or selling T1 devices in their stores,' they write. 'It is critical that federal regulators continue to evenhandedly enforce competition and consumer protection laws against Trump Mobile and any companies with which it works, especially in the face of this opportunity for corruption and self-dealing for President Trump.' Posts from this author will be added to your daily email digest and your homepage feed. See All by Lauren Feiner Posts from this topic will be added to your daily email digest and your homepage feed. See All Exclusive Posts from this topic will be added to your daily email digest and your homepage feed. See All Gadgets Posts from this topic will be added to your daily email digest and your homepage feed. See All Phones Posts from this topic will be added to your daily email digest and your homepage feed. See All Policy Posts from this topic will be added to your daily email digest and your homepage feed. See All Politics Posts from this topic will be added to your daily email digest and your homepage feed. See All Regulation Posts from this topic will be added to your daily email digest and your homepage feed. See All Report
Yahoo
10 minutes ago
- Yahoo
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the 24-month DOR of 72.2% (95% CI 64.1%, 78.8%) by Kaplan-Meier estimate in patients who achieved CR at three months from the Phase 3 ENVISION trial of ZUSDURI™ (mitomycin) for intravesical solution, a treatment for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The median follow-up time after a three-month CR in this analysis was 23.7 months. The median DOR has not been reached. 'This latest update from the pivotal ENVISION trial of ZUSDURI showed that, among patients who achieved a complete response at three months, the probability of remaining event-free 24 months after CR was 72.2%,' said Sandip Prasad, M.D., Director of Genitourinary Surgical Oncology and Vice Chair of Urology at Morristown Medical Center/Atlantic Health System, NJ, and Principal Investigator of the ENVISION trial. 'Among patients who achieved a complete response, the event rate over time has remained stable. This DOR result highlights the sustained efficacy of the therapy and reinforces its potential as a durable treatment option. For the first time, adult patients with recurrent LG-IR-NMIBC have an FDA-approved therapy. This marks a potentially transformative step forward in how we manage this chronic, highly recurrent, and disruptive cancer. ZUSDURI is a new, outpatient treatment option for patients that can help provide a clinically meaningful recurrence-free interval, which is compelling given the highly recurrent nature of LG-IR-NMIBC.' The existing standard of care for LG-IR-NMIBC is a surgical procedure typically conducted under general anesthesia called transurethral resection of bladder tumor (TURBT). Repeated TURBT procedures can impact patients' physical health and quality of life and can even be associated with an increased risk in mortality. Due to high recurrence rates, LG-IR-NMIBC patients, who are typically elderly with comorbidities, will likely need multiple TURBTs under general anesthesia over the course of their lifetime. An estimated 59,000 patients with LG-IR-NMIBC recur annually. According to Mark Schoenberg, M.D., Chief Medical Officer, UroGen, 'The 24-month duration of response data from the ENVISION trial underscore the transformative potential of ZUSDURI (formerly known as UGN-102) for adult patients with recurrent LG-IR-NMIBC. This is a population that has long endured a cycle of recurrence and repeat surgeries, a burden that weighs heavily, particularly on older adults. With ZUSDURI now approved, we have a new treatment option that can help deliver durable complete responses and meaningfully extend event-free intervals. This represents a major advance in the way we care for these patients.' The most common (≥ 10%) adverse reactions (ARs), including laboratory abnormalities, that occurred in patients were dysuria, increased potassium, increased creatinine, decreased hemoglobin, increased eosinophils, increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria. ARs were mainly mild to moderate. Serious ARs occurred in 12% of patients, including urinary retention (0.8%) and urethral stenosis (0.4%). About ZUSDURI ZUSDURI (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, approved for the treatment of adults with recurrent LG-IR-NMIBC. Utilizing UroGen's proprietary RTGel® technology (a sustained release, hydrogel-based formulation), ZUSDURI is delivered directly into the bladder by a trained healthcare professional using a urinary catheter in an outpatient setting, thereby enabling the treatment of tumors by non-surgical means. About Non-Muscle Invasive Bladder Cancer (NMIBC) LG-IR-NMIBC affects around 82,000 people in the U.S. every year and of those, an estimated 59,000 are recurrent. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include TURBT as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence, and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures. Learn more about non-muscle invasive bladder cancer at About ENVISIONThe Phase 3 ENVISION trial is a single-arm, multinational, multicenter pivotal study evaluating the efficacy and safety of ZUSDURI (mitomycin) for intravesical solution as a chemoablative therapy in adult patients with recurrent LG-IR-NMIBC. The Phase 3 ENVISION trial completed target enrollment with 240 patients across 56 sites. Study participants received six once-weekly intravesical instillations of ZUSDURI. The primary endpoint evaluated the CR rate at three months after the first instillation, and the key secondary endpoint evaluates durability over time in patients who achieved a CR at the three-month assessment. Learn more about the Phase 3 ENVISION trial at (NCT05243550). About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and our second product, ZUSDURI (mitomycin) for intravesical solution for adult patients with recurrent LG-IR-NMIBC, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit to learn more or follow us on X (Twitter), @UroGenPharma. IMPORTANT SAFETY INFORMATIONAPPROVED USE FOR ZUSDURI ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after previously receiving bladder surgery to remove tumor that did not work or is no longer working. IMPORTANT SAFETY INFORMATION You should not receive ZUSDURI if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI. Before receiving ZUSDURI, tell your healthcare provider about all of your medical conditions, including if you: have kidney problems are pregnant or plan to become pregnant. ZUSDURI can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI and for 6 months after the last dose. Males being treated with ZUSDURI: You should use effective birth control (contraception) during treatment with ZUSDURI and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ZUSDURI passes into your breast milk. Do not breastfeed during treatment with ZUSDURI and for 1 week after the last dose. How will I receive ZUSDURI? You will receive your ZUSDURI dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. During treatment with ZUSDURI, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving ZUSDURI: ZUSDURI may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. The most common side effects of ZUSDURI include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, and blood in your urine. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information. ZUSDURI™ is a trademark and UroGen® is a registered trademark of UroGen Pharma, Ltd. Copyright©2025 UroGen Pharma, Inc. All rights reserved. Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential benefits of ZUSDURI, including as an outpatient treatment option, its potential to provide durable CRs and clinically meaningful recurrence-free intervals and as a compelling alternative to TURBT given the high recurrence rates of LG-IR-NMIBC; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential of UroGen's proprietary RTGel technology to improve therapeutic profiles of existing drugs other than mitomycin; and UroGen's sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as 'can,' 'estimate,' 'likely,' 'may,' 'potential,' 'will' or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: clinical results may not be indicative of results that may be observed in the future, including in larger populations; potential safety and other complications related to UroGen's products; the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen's industry; the scope, progress and expansion of developing and commercializing UroGen's products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen's ability to attract or retain key management, members of the board of directors and other personnel; UroGen's RTGel technology and ZUSDURI may not perform as expected; UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology; and the impacts of general macroeconomic and geopolitical conditions on UroGen's business and financial position. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release. INVESTOR CONTACT:Vincent PerroneSenior Director, Investor ext. 1093 MEDIA CONTACT:Cindy RomanoDirector, Corporate ext. 1083Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Henry Schein's 2025 Outlook Hinges On Strong Second-Half Execution
Henry Schein Inc. (NASDAQ:HSIC) stock is trading lower on Tuesday after the company reported its second-quarter earnings. The global healthcare solutions company reported adjusted earnings of $1.10 per share, down 10.6% year over year, missing the consensus of $1.20. Sales were $3.24 billion, beating the consensus of $3.22 billion. As reported, total net sales increased by 3.3%, reflecting 1.9% internal sales growth, 0.8% sales growth from acquisitions, and a 0.6% sales increase resulting from foreign currency Distribution and Value-Added Services sales for the quarter increased 2.9%, and by 2.4% in constant currencies compared with the second quarter of 2024. Total Global Distribution and Value-Added Services sales reached $2.73 billion, up from $2.65 billion a year ago. Henry Schein said Global Dental Distribution equipment sales for the quarter increased 3.0%, and by 1.6% in constant currencies. Sales growth was strong internationally and offset by lower sales in the U.S., resulting from a slowdown in orders beginning in May due to short-term economic uncertainty resulting from tariffs, which then returned to normal by the end of the quarter. Global Specialty Products sales for the quarter increased 4.2%, and by 3.3% to $386 million in constant currencies compared with the second quarter of 2024, reflecting continued growth in implant and biomaterial sales and endodontic consumables, offset partly by lower orthodontic sales. View more earnings on HSIC Global Technology sales for the quarter increased 7.4%, and by 6.6% in constant currencies to $167 million, reflecting strong sales growth in practice management systems, including Dentrix Ascend and Dentally cloud-based solutions, as well as in revenue cycle management products. 'Partnering with KKR Capstone, we have engaged two leading global management consulting firms to support our efforts to enhance distribution gross margins, including accelerating sales of our owned-products portfolio, and to support our ongoing company-wide initiatives to increase efficiencies. We expect these projects, which expand on our BOLD+1 strategy, to start producing results towards the beginning of 2026, and will support our ongoing initiatives to drive superior customer satisfaction and our financial goal of high-single digit to low-double digit earnings growth,' said Stanley Bergman, Chairman and CEO of Henry Schein. During the second quarter of 2025, the company recorded $23 million in restructuring costs and expects to achieve annual run-rate savings of over $100 million by the end of 2025. Outlook Henry Schein affirms fiscal 2025 adjusted earnings guidance of $4.80-$4.94 per share versus the consensus of $4.88. The company maintains 2025 sales guidance of $12.43 billion-$13.18 billion compared to the consensus of $12.96 billion. Adding a forward-looking perspective, investment firm William Blair said, 'Management also provided informal 2026 guidance for high-single- to low-double-digit EPS growth as the business stabilizes in 2025 and it starts to see some early benefits of its partnership with KKR and two other consulting firms. Consensus for 2026 currently calls for 8% EPS growth, so this is a welcome update, and we look for more concrete details on what these partnerships entail on the second-quarter call.' 'Overall, updates are mixed, and while we acknowledge management's execution on commercial/partner efforts, we expect second-half execution will be critical for durable valuation and share upside,' analyst Brandon Vazquez wrote in an investor note on Tuesday. Price Action: HSIC stock is trading lower by 8.80% to $64.37 at last check Tuesday. Read Next:Photo via Shutterstock Latest Ratings for HSIC Date Firm Action From To Feb 2022 Morgan Stanley Maintains Underweight Feb 2022 Credit Suisse Maintains Outperform Jan 2022 Morgan Stanley Initiates Coverage On Underweight View More Analyst Ratings for HSIC View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? HENRY SCHEIN (HSIC): Free Stock Analysis Report This article Henry Schein's 2025 Outlook Hinges On Strong Second-Half Execution originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
